Articles Tagged With:
-
Pharmacology Watch: Linking COX-2 Inhibitors and Cardiovascular Event Risk
A new and as yet unpublished study has raised increased concern about the relationship between rofecoxib (Vioxx), Mercks blockbuster COX-2 inhibitor, and cardiovascular events. -
Full October 15, 2004, Issue in PDF
-
Sayonara, Sinus Headaches
Headaches commonly attributed to sinus are very likely to be migraines. -
Resolution of Hepatitis C Infection
Studies on HCV infection resolution show that PBMC HCV-RNA may remain, despite clearance of the virus from plasma. -
Pharmacology Update: Acamprosate Calcium Tablets (Campral®)
The FDA has approved a new drug for the management of alcohol dependence. -
Essential information for permanent weight loss
Before people can eat a balanced diet, they must understand nutrition; therefore, some education about nutrition is needed. -
Erythromycin and the Heart
Erythromycin use is associated with a 2-fold increased risk of sudden cardiac death and a 5-fold increase in those who concurrently receive other medications that significantly inhibit its metabolism by CYP3A4. -
Rifaximin: Another Choice for Treatment of Travelers’ Diarrhea
Rifaximin (Xifaxan) has rreceived US FDA approval on May 25, 2004, for the treatment of travelers diarrhea caused by enteropathogenic (non-invasive) Eschericiha coli in individuals at least 12 years of age. Rifaximin is a rifamycin that is poorly absorbed (< 0.4%) from the gastrointestinal tract, and thus achieves very high concentrations in the feces. -
Clinical Briefs in Primary Care supplement
-
Full October 2004 issue in PDF